Literature DB >> 2086491

N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.

W Siegmund1, W Hanke, M Zschiesche, G Franke, K E Biebler, A Wilke.   

Abstract

Phenotypes of the N-acetylation and debrisoquine type oxidation polymorphism were determined with sulfamethazine and debrisoquine in 145 healthy volunteers (31-80 years, 64 males, 81 females) of a North-East German area. Seventeen (11.7%) were poor metabolizers of debrisoquine and 81 (55.9%) slow acetylators of sulfamethazine. No significant correlations between the frequencies of oxidation and acetylation phenotypes, age, and sex were found. Only a tendency of rapid acetylators to accumulate among individuals above 60 years was noticed. Parameters of phenotyping were not influenced by sex. With age, metabolic ratios of N-acetylation but not of oxidation phenotyping increased. The urinary excretion (0-8 hours) of debrisoquine, sulfamethazine and their metabolites was strikingly reduced in the elderly. Misclassifications of acetylation phenotyping cannot be excluded because of the age dependent kinetics of the test drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2086491

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  6 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

2.  Tiracizine disposition in healthy volunteers with reference to the debrisoquine oxidation phenotype.

Authors:  A Berndt; C Hoffmann; K Richter; R Oertel; A Vierkant; W Siegmund
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

3.  Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.

Authors:  C Müller; W Siegmund; R Huupponen; T Kaila; G Franke; E Iisalo; M Zschiesche
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

4.  Debrisoquine oxidation polymorphism in patients with rheumatoid arthritis.

Authors:  J Benitez; J M Ladero; M P Andres; J A Jover; C Morado; A Bañares
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

5.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

6.  Debrisoquine hydroxylation in a Polish population.

Authors:  P K Kunicki; D Sitkiewicz; A Pawlik; V Bielicka-Sulzyc; E Borowiecka; B Gawrońska-Szklarz; R Sterna; H Matsumoto; M Radziwoń-Zaleska
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.